Biotech Values

[DewDiligence]

MRNA/ABUS—From the same source:

Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle technology.

…In a hearing Thursday, Moderna unsuccessfully argued Arbutus' claims shouldn't be patented, SVB Leerink analyst Mani Foroohar said in a report. He called the decision in Arbutus' favor "a disappointing turn for Moderna." Moderna stock crumbled just before the stock market's close.

…The result opens the door to debate around Moderna's entire pipeline, Foroohar said.